Neuboron Medtech, a BNCT total solution provider, enters Joint-Venture Agreement with TAE Life Sciences, further consolid
Neuboron Therapy System (NTS), a wholly owned subsidiary of Neuboron Medtech, announced today it has approved an approximate USD 10 million of minority equity investment from TAE Life Sciences (TLS), a US-based leading manufacturer of Vacuu Neuboron Medtech Ltd starts construction work for the first AB-BNCT manufacturing facility in Xiamen, China
Neuboron Medtech has officially started the Phase I construction of Accelerator Based Boron Neutron Captured Therapy (AB-BNCT) manufacture facility in Spring 2019, and this facility is expected to put into operation by Fall 2019.